Literature DB >> 17438459

Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.

Suzanne Q van Veen1, Joost C M Meijers, Marcel Levi, Thomas M van Gulik, Marja A Boermeester.   

Abstract

Peritonitis represents a procoagulant state because of activated coagulation and inhibited fibrinolysis. Intra-abdominal fibrin deposition-entrapping bacteria-prevents bacterial spread but impairs bacterial clearance. Activating intra-abdominal fibrinolysis by recombinant tissue-type plasminogen activator (r-tPA) early during peritonitis may enhance bacterial clearance and reduce inflammation. This study examines effects of abdominal r-tPA lavage on local and distant coagulation, fibrinolysis, and inflammatory responses in experimental polymicrobial peritonitis. Twenty-four hours after cecal ligation and puncture, mice were exposed to therapeutic abdominal lavage with varying doses of r-tPA or saline (controls). Coagulation, fibrinolysis, and inflammation were assessed in abdominal, systemic, and pulmonary compartments (n = 6 per group per time point). Survival was assessed during 96 h (n = 16 per group). Highest-dose (2 mg/mL) r-tPA lavage caused immediate death. High-dose (0.5 mg/mL) r-tPA lavage increased fibrinolysis, demonstrated by low abdominal plasminogen activator inhibitor 1 levels and elevated pulmonary tPA levels, resulting in reduced abdominal bacterial load, chemokine levels, leukocyte influx, and thrombin generation, along with less pulmonary fibrin depositions and organ damage on histological examination (P < 0.05 vs. saline lavage). Low-dose (0.05 mg/mL) r-tPA lavage showed hardly any effect compared with saline lavage. Adversely, abdominal and plasma interleukin (IL) 12 were elevated, whereas IL-10 levels were decreased after high-dose r-tPA lavage (P < 0.05 vs. saline). Survival rate was not affected by any dose of r-tPA lavage compared with saline lavage. Delayed local stimulation of fibrinolysis by peritoneal r-tPA lavage enhanced intra-abdominal bacterial clearance and reduced intra- and extra-abdominal coagulation responses in a dose-dependent manner. Survival rate was unaffected likely due to adverse changes in IL-12 and IL-10 levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17438459     DOI: 10.1097/01.shk.0000246897.27574.1b

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  5 in total

1.  Human Neutrophils Support Thrombin Generation in Peritonitis.

Authors:  Souad Lakbakbi; Alexandre Debrumetz; Philippe Rieu; Philippe Nguyen
Journal:  Perit Dial Int       Date:  2015 Sep-Oct       Impact factor: 1.756

2.  Tissue plasminogen activator attenuates ventilator-induced lung injury in rats.

Authors:  Liang-ti Huang; Hsiu-chu Chou; Leng-fang Wang; Chung-ming Chen
Journal:  Acta Pharmacol Sin       Date:  2012-07-16       Impact factor: 6.150

3.  Efficacy and safety of active negative pressure peritoneal therapy for reducing the systemic inflammatory response after damage control laparotomy (the Intra-peritoneal Vacuum Trial): study protocol for a randomized controlled trial.

Authors:  Derek J Roberts; Craig N Jenne; Chad G Ball; Corina Tiruta; Caroline Léger; Zhengwen Xiao; Peter D Faris; Paul B McBeth; Christopher J Doig; Christine R Skinner; Stacy G Ruddell; Paul Kubes; Andrew W Kirkpatrick
Journal:  Trials       Date:  2013-05-16       Impact factor: 2.279

Review 4.  Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases.

Authors:  Margaret Markiewicz; Erin Richard; Natalia Marks; Anna Ludwicka-Bradley
Journal:  J Aging Res       Date:  2013-10-28

5.  Hypofibrinolysis induced by tranexamic acid does not influence inflammation and mortality in a polymicrobial sepsis model.

Authors:  Yzabella Alves Campos Nogueira; Loredana Nilkenes Gomes da Costa; Carlos Emilio Levy; Fernanda Andrade Orsi; Franciele de Lima; Joyce M Annichinno-Bizzacchi; Erich Vinicius De Paula
Journal:  PLoS One       Date:  2019-12-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.